Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA.

J Clin Invest. 2019 Nov 1;129(11):4992-5004. doi: 10.1172/JCI127967.

2.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
3.

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC.

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. No abstract available.

4.

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.

Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger D, Malekzadeh P, Shelton TE, Prickett T, Ray S, Kivitz S, Paria BC, Kriley I, Schrump DS, Rosenberg SA.

Cancer Immunol Res. 2019 Apr;7(4):534-543. doi: 10.1158/2326-6066.CIR-18-0686. Epub 2019 Feb 1. Review.

5.

Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.

Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA.

Nat Commun. 2019 Jan 25;10(1):449. doi: 10.1038/s41467-019-08304-z.

6.

Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA.

JCI Insight. 2018 Oct 4;3(19). pii: 122467. doi: 10.1172/jci.insight.122467.

7.

Encouraging local ownership of an externally-coordinated capacity building initiative in Malawi, Mali, Mozambique, and Tanzania: an exercise in process evaluation.

Vignola E, Parkhurst M, Misomali A, Heidkamp R.

J Glob Health. 2018 Jun;8(1):010304. doi: 10.7189/jogh.08.010304. Review. No abstract available.

8.

Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.

Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, Rosenberg SA.

Clin Cancer Res. 2017 May 15;23(10):2491-2505. doi: 10.1158/1078-0432.CCR-16-2680. Epub 2016 Nov 8.

9.

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.

Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner J, Trebska-McGowan K, Crystal JS, Rosenberg SA.

Cancer Immunol Res. 2016 Sep 2;4(9):734-43. doi: 10.1158/2326-6066.CIR-16-0001. Epub 2016 Jun 28.

10.

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.

Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF.

Cancer Immunol Res. 2016 Aug;4(8):669-78. doi: 10.1158/2326-6066.CIR-15-0215. Epub 2016 Jun 16.

11.

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA.

Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.

12.

A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.

Jaigirdar A, Rosenberg SA, Parkhurst M.

J Immunother. 2016 Apr;39(3):105-16. doi: 10.1097/CJI.0000000000000116.

13.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA.

Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.

PMID:
26901407
14.

A test of core psychopathic traits as a moderator of the efficacy of a brief motivational intervention for substance-using offenders.

Swogger MT, Conner KR, Caine ED, Trabold N, Parkhurst MN, Prothero LM, Maisto SA.

J Consult Clin Psychol. 2016 Mar;84(3):248-58. doi: 10.1037/ccp0000065. Epub 2016 Jan 4. Erratum in: J Consult Clin Psychol. 2016 Mar;84(3):210.

15.

Enhancing Community-Based Participatory Research Partnerships Through Appreciative Inquiry.

Paige C, Peters R, Parkhurst M, Beck LL, Hui B, May VT, Tanjasiri SP.

Prog Community Health Partnersh. 2015 Autumn;9(3):457-63. doi: 10.1353/cpr.2015.0054.

16.

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.

17.

Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations.

Smith SM, Hunsinger M, McKeown A, Parkhurst M, Allen R, Kopko S, Lu Y, Wilson HD, Burke LB, Desjardins P, McDermott MP, Rappaport BA, Turk DC, Dworkin RH.

J Pain. 2015 Apr;16(4):299-305. doi: 10.1016/j.jpain.2015.01.004. Epub 2015 Jan 28. Review.

PMID:
25637296
18.

Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review.

Hunsinger M, Smith SM, Rothstein D, McKeown A, Parkhurst M, Hertz S, Katz NP, Lin AH, McDermott MP, Rappaport BA, Turk DC, Dworkin RH.

Pain. 2014 Nov;155(11):2253-62. doi: 10.1016/j.pain.2014.08.004. Epub 2014 Aug 12. Review.

PMID:
25123543
19.

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.

Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.

20.

A novel murine T-cell receptor targeting NY-ESO-1.

Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.

J Immunother. 2014 Apr;37(3):135-46. doi: 10.1097/CJI.0000000000000019.

PMID:
24598449
21.

Disclosure of authorship contributions in analgesic clinical trials and related publications: ACTTION systematic review and recommendations.

Hunsinger M, Smith SM, McKeown A, Parkhurst M, Gross RA, Lin AH, McDermott MP, Rappaport BA, Turk DC, Dworkin RH.

Pain. 2014 Jun;155(6):1059-63. doi: 10.1016/j.pain.2013.12.011. Epub 2013 Dec 12. Review. No abstract available.

PMID:
24334187
22.

Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition.

Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR.

J Acad Nutr Diet. 2013 Sep;113(9):1219-37. doi: 10.1016/j.jand.2013.05.015. Epub 2013 Jul 17.

23.

Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition.

Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR.

Medsurg Nurs. 2013 May-Jun;22(3):147-65.

PMID:
23865276
24.

Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition.

Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR.

JPEN J Parenter Enteral Nutr. 2013 Jul;37(4):482-97. doi: 10.1177/0148607113484066. Epub 2013 Jun 4.

PMID:
23736864
25.

Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study.

Gracious BL, Finucane TL, Friedman-Campbell M, Messing S, Parkhurst MN.

BMC Psychiatry. 2012 May 9;12:38. doi: 10.1186/1471-244X-12-38.

26.

Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.

Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME.

J Transl Med. 2012 Apr 4;10:69. doi: 10.1186/1479-5876-10-69.

27.

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.

Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA.

Clin Cancer Res. 2011 Oct 1;17(19):6287-97. doi: 10.1158/1078-0432.CCR-11-1347. Epub 2011 Aug 15.

28.

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.

Mol Ther. 2011 Mar;19(3):620-6. doi: 10.1038/mt.2010.272. Epub 2010 Dec 14.

29.

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.

J Immunol. 2011 Jan 15;186(2):685-96. doi: 10.4049/jimmunol.1001775. Epub 2010 Dec 13.

30.

Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA.

Hum Gene Ther. 2011 Jan;22(1):107-15. doi: 10.1089/hum.2010.064. Epub 2010 Dec 12.

31.

Conclusions of the Capstone depleted uranium aerosol characterization and risk assessment study.

Parkhurst MA, Guilmette RA.

Health Phys. 2009 Mar;96(3):393-409. doi: 10.1097/01.HP.0000339006.09037.56.

PMID:
19204494
32.

Applications of Capstone depleted uranium aerosol risk data to military combat risk management.

Daxon EG, Parkhurst MA, Melanson MA, Roszell LE.

Health Phys. 2009 Mar;96(3):380-92. doi: 10.1097/01.HP.0000341958.98248.00.

PMID:
19204493
33.

Inhalation and ingestion intakes with associated dose estimates for level II and level III personnel using Capstone study data.

Szrom F, Falo GA, Lodde GM, Parkhurst MA, Daxon EG.

Health Phys. 2009 Mar;96(3):363-79. doi: 10.1097/01.HP.0000334063.95622.f9.

PMID:
19204492
34.

Radiological risk assessment of Capstone depleted uranium aerosols.

Hahn FF, Roszell LE, Daxon EG, Guilmette RA, Parkhurst MA.

Health Phys. 2009 Mar;96(3):352-62. doi: 10.1097/01.hp.0000318891.68749.66.

PMID:
19204491
35.

Assessing the renal toxicity of Capstone depleted uranium oxides and other uranium compounds.

Roszell LE, Hahn FF, Lee RB, Parkhurst MA.

Health Phys. 2009 Mar;96(3):343-51. doi: 10.1097/01.HP.0000338421.07312.ed.

PMID:
19204490
36.

Capstone depleted uranium aerosol biokinetics, concentrations, and doses.

Guilmette RA, Miller G, Parkhurst MA.

Health Phys. 2009 Mar;96(3):328-42. doi: 10.1097/01.HP.0000338296.54391.1c.

PMID:
19204489
37.

Physicochemical characterization of Capstone depleted uranium aerosols III: morphologic and chemical oxide analyses.

Krupka KM, Parkhurst MA, Gold K, Arey BW, Jenson ED, Guilmette RA.

Health Phys. 2009 Mar;96(3):276-91. doi: 10.1097/01.HP.0000298229.60229.10.

PMID:
19204486
38.

Physicochemical characterization of Capstone depleted uranium aerosols II: particle size distributions as a function of time.

Cheng YS, Kenoyer JL, Guilmette RA, Parkhurst MA.

Health Phys. 2009 Mar;96(3):266-75. doi: 10.1097/01.HP.0000290613.41486.cb.

PMID:
19204485
39.

Physicochemical characterization of Capstone depleted uranium aerosols I: uranium concentration in aerosols as a function of time and particle size.

Parkhurst MA, Cheng YS, Kenoyer JL, Traub RJ.

Health Phys. 2009 Mar;96(3):251-65. doi: 10.1097/01.HP.0000311549.85594.a3.

PMID:
19204484
40.

Calculating Capstone depleted uranium aerosol concentrations from beta activity measurements.

Szrom F, Falo GA, Parkhurst MA, Whicker JJ, Alberth DP.

Health Phys. 2009 Mar;96(3):238-50. doi: 10.1097/01.HP.0000290612.27848.cd.

PMID:
19204483
41.

Aerosol sampling system for collection of Capstone depleted uranium particles in a high-energy environment.

Holmes TD, Guilmette RA, Cheng YS, Parkhurst MA, Hoover MD.

Health Phys. 2009 Mar;96(3):221-37. doi: 10.1097/01.HP.0000290610.53663.57.

PMID:
19204482
42.
43.

Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.

Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA.

Clin Cancer Res. 2009 Jan 1;15(1):169-80. doi: 10.1158/1078-0432.CCR-08-1638.

44.

Dose assessment for inhalation intakes in complex, energetic environments: experience from the US Capstone study.

Guilmette RA, Parkhurst MA.

Radiat Prot Dosimetry. 2007;127(1-4):516-20. Epub 2007 Aug 31.

PMID:
17766261
45.

Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.

Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.

Cancer Res. 2007 Mar 15;67(6):2425-9.

46.

Feeding practices of severely ill intensive care unit patients: an evaluation of energy sources and clinical outcomes.

Hise ME, Halterman K, Gajewski BJ, Parkhurst M, Moncure M, Brown JC.

J Am Diet Assoc. 2007 Mar;107(3):458-65.

PMID:
17324665
47.

Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.

Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR.

J Immunother. 2006 Nov-Dec;29(6):616-27.

49.

Evidence-based clinical practice: dispelling the myths.

Hise ME, Kattelmann K, Parkhurst M.

Nutr Clin Pract. 2005 Jun;20(3):294-302. Review.

PMID:
16207666
50.

Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.

Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S.

Dev Biol (Basel). 2004;116:169-78; discussion 179-86.

PMID:
15603192

Supplemental Content

Loading ...
Support Center